A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination

por Sax, Paul E, Dejesus, Edwin, Crofoot, Gordon, Ward, Douglas, Benson, Paul, Wei, Lilian, White, Kirsten, Collins, Sean, Martin, Hal, Cheng, Andrew, Quirk, Erin
Publicado 2017

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings

por Cooper, David A., Heera, Jayvant, Ive, Prudence, Botes, Mariette, Dejesus, Edwin, Burnside, Robert, Clumeck, Nathan, Walmsley, Sharon, Lazzarin, Adriano, Mukwaya, Geoffrey, Saag, Michael, van Der Ryst, Elna
Publicado 2014

Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study

por Sutton, Kenneth C, De Vente, Jerome, Leblanc, Roger, Dejesus, Edwin, Smith, Graham, Mills, Anthony, Baril, Jean-Guy, St. Clair, Marty, Stancil, Britt S, Vandermeulen, Kati, Spreen, William R
Publicado 2022